Search Result

Results for "

induces reprogramming

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Apoptosis (4) ATP Synthase (1) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (1) Casein Kinase (1) Caspase (1) CDK (1) COX (3) DNA/RNA Synthesis (1) Farnesyl Transferase (1) IKZF Family (2) Interleukin Related (1) JNK (1) Macrophage migration inhibitory factor (MIF) (1) MMP (1) Molecular Glues (2) NF-κB (1) NO Synthase (1) Oct3/4 (2) Oxidative Phosphorylation (1) PI3K (1) Protein Arginine Deiminase (1) Pyruvate Kinase (1) Ras (1) Reactive Oxygen Species (ROS) (3) Reference Standards (2) RNA MTase (1) ROCK (1) SGK (1) Sirtuin (2) Stearoyl-CoA Desaturase (SCD) (1) Tau Protein (1) TET Protein (1) TGF-β Receptor (2)
By Research Areas:	Cancer (13) Infection (1) Inflammation/Immunology (8) Neurological Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12303

OAC1 1 Publications Verification	Oct3/4 TET Protein	Cancer
OAC1 is a potent Oct4 activator. OAC1 activates Oct4 and Nanog promoters and enhances induced pluripotent stem cells (iPSC) formation. OAC1 activates OCT4 through upregulation of HOXB4 expression. OAC1 increases transcription of the Oct4-Nanog-Sox2 triad and TET1. OAC1 facilitates the reprogramming of cells by enhancing efficiency and shortening the reprogramming time .

HY-N1511

Ganoderic acid D 2 Publications Verification	Sirtuin Apoptosis	Cancer
Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .

HY-178159

SA91-0178	RNA MTase	Inflammation/Immunology
SA91-0178 is a METTL1 inhibitor. SA91-0178 inhibits m ⁷G methylation of RNA, reduces SARM1 stability, mitigates NAD ⁺ depletion and metabolic reprogramming in macrophages. SA91-0178 demonstrates excellent protective efficacy against multiple organ injury in cecal ligation and puncture (CLP)-induced and ischemia/reperfusion (I/R)-induced mice. SA91-0178 can be used for the study of systemic inflammatory diseases .

HY-173630

BMS-986449	Molecular Glues IKZF Family	Cancer
BMS-986449 is a potent and orally active CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatory T (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors .

HY-114858

Epiblastin A 1 Publications Verification	Casein Kinase	Cancer
Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC₅₀s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1 .

HY-141591

CYT296	Biochemical Assay Reagents	Others
CYT296 is a target chromatin de-condensation compound. CYT296 can improve the induction of induced pluripotent stem cell (iPSCs) mediated by defined factors (OSKM) and induce an open chromatin state in Mouse Embryonic Fibroblast (MEFs) to facilitate somatic cell reprogramming. CYT296 can be used for cell replacement therapies and drug screening research .

HY-167832

PT109	JNK SGK ROCK Tau Protein MMP DNA/RNA Synthesis Pyruvate Kinase NF-κB COX NO Synthase Reactive Oxygen Species (ROS)	Neurological Disease Cancer
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .

HY-P99746

Murlentamab 3C23K; GM102	TGF-β Receptor	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

HY-174976

FHND5032	PI3K Akt Interleukin Related Bacterial	Inflammation/Immunology
FHND5032 is an orally active miR-124 inducer. FHND5032 significantly upregulates miR-124 expression in macrophages. FHND5032 disrupts inflammatory signaling, promotes macrophage reprogramming, and restores the epithelial barrier function by inhibiting the PIK3R2/PI3K/Akt axis. FHND5032 alleviates colitis and reduces inflammatory burden in ulcerative colitis mice. FHND5032 can be used for the study of ulcerative colitis .

HY-173630A

(Rac)-BMS-986449	Molecular Glues IKZF Family	Cancer
(R)-BMS-986449 is the racemic mixture of BMS-986449 (HY-173630). BMS-986449 is a CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatory T (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors .

HY-N3388

Licoisoflavone B	Stearoyl-CoA Desaturase (SCD)	Infection Inflammation/Immunology Cancer
Licoisoflavone B is an orally active flavonoid found in licorice. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Licoisoflavone B inhiibits superoxide anion generation and superoxide anion-induced lipid peroxidation. Licoisoflavone B binds tightly to Lassa virus nucleoprotein and can be used as a nucleoprotein antagonist of Lassa virus. Licoisoflavone B exhibits anti-mutagenic activity against carcinogenic mutagen, by preventing DNA damage. Licoisoflavone B can be used for the research of psoriasis, Lassa fever, inflammation and cancer .

HY-119672

Oct4 inducer-1	Oct3/4	Others
Oct4 inducer-1 (compound OAC-3) is a potent Oct4 activator. Oct4 inducer-1 activates Oct4 and Nanog promoters and enhances induced pluripotent stem cells (iPSC) formation. Oct4 inducer-1 facilitates the reprogramming of cells by enhancing efficiency and shortening the reprogramming time .

HY-116428

L-744832	Farnesyl Transferase Ras TGF-β Receptor Apoptosis	Cancer
L-744832 is a farnesyl transferase inhibitor. L-744832 effectively inhibits the farnesylation of H-Ras and N-Ras, but has little effect on K-Ras treatment. L-744832 not only directly targets the oncogenic pathway by inhibiting Ras farnesylation, but also enhances radiosensitivity by restoring TGF-β signaling through epigenetic reprogramming. L-744832 can induce cell cycle arrest and apoptosis. L-744832 can be used in combination therapy studies for Ras-driven tumors such as pancreatic cancer .

HY-173624

TE-11	Macrophage migration inhibitory factor (MIF)	Inflammation/Immunology
TE-11 is a MIF tautomerase inhibitor with an IC₅₀ of 5.63 μM. TE-11 ameliorates CD-like colitis, reduces MIF-induced eosinophil and neutrophil migration, and prevents M1 polarization and associated metabolic reprogramming .

HY-155031

MCI	Reactive Oxygen Species (ROS) COX	Inflammation/Immunology Cancer
MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC₅₀ value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA) .

HY-N1511R

Ganoderic acid D (Standard)	Reference Standards Sirtuin Apoptosis	Cancer
Ganoderic acid D (Standard) is the analytical standard of Ganoderic acid D. This product is intended for research and analytical applications. Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .

HY-N0272R

Eleutheroside E (Standard)	Reference Standards Others	Inflammation/Immunology
Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis .

HY-P11869

PADI4_11	Protein Arginine Deiminase	Inflammation/Immunology
PADI4_11 is an isoform-selective, allosteric PADI4 activator with a K_d of 457 nM. PADI4_11 enters cells via active transport, does not induce cytotoxicity or membrane damage, and serves as a tool for investigating the regulation, function and cellular reprogramming of PADI4. PADI4_11 can be used in studies related to rheumatoid arthritis and ulcerative colitis .

HY-181483

CDK6-IN-2	CDK Reactive Oxygen Species (ROS) Apoptosis Autophagy Caspase	Cancer
CDK6-IN-2 is a CDK6 covalent inhibitor with an IC₅₀ of 0.013 μM. CDK6-IN-2 inhibits the proliferation and migration of triple-negative breast cancer cells, and induces cell cycle arrest and apoptosis. CDK6-IN-2 induces ROS accumulation and mitochondrial damage through cellular metabolic reprogramming. CDK6-IN-2 exhibits anti-tumor activity and can be used for the research of triple-negative breast cancer .

HY-181602

ATP Synthesis-IN-4	ATP Synthase COX Oxidative Phosphorylation AMPK	Cancer
ATP Synthesis-IN-4 is a mitochondria-targeted small-molecule ligand that inhibits ATP synthesis. ATP Synthesis-IN-4 binds to mtDNA G4s in melanoma cells, thereby inducing changes in mitochondrial metabolism and inhibiting cell proliferation. ATP Synthesis-IN-4 suppresses the translation of key mitochondrial respiratory chain proteins (CYTB, ATP8, COX1, COX3, ND2) in melanoma cells, downregulates the expression of OXPHOS complexes, activates the phosphorylation of AMPK, and induces metabolic reprogramming to upregulate glycolysis. ATP Synthesis-IN-4 is applicable to relevant research on melanoma .

Cat. No.	Product Name

HY-L039

Reprogramming Compound Library	3,086 compounds
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells. MCE Reprogramming Compound Library contains a unique collection of 3,086 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

Reprogramming Compound Library

3,086 compounds

Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.

MCE Reprogramming Compound Library contains a unique collection of 3,086 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

HY-L038

Differentiation Inducing Compound Library	2,405 compounds
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method. MCE Differentiation Inducing Compound Library contains a unique collection of 2,405 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.

Differentiation Inducing Compound Library

2,405 compounds

Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.

MCE Differentiation Inducing Compound Library contains a unique collection of 2,405 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.

Cat. No.	Product Name	Target	Research Area